Skip to main content
Top
Published in: Indian Journal of Pediatrics 5/2024

20-06-2023 | Chronic Inflammatory Bowel Disease | Review Article

Inflammatory Bowel Disease in Children

Authors: Asha Jois, George Alex

Published in: Indian Journal of Pediatrics | Issue 5/2024

Login to get access

Abstract

Inflammatory bowel disease is an important cause of chronic diarrhea in children, with a rising incidence, globally. The two main subtypes include Crohn’s disease and ulcerative colitis. The clinical features are variable, and diagnosis requires initial first-line investigations followed by the involvement of specialist input for targeted imaging and endoscopy with biopsy, to confirm the diagnosis. Despite detailed investigation, inflammatory bowel disease may be clinically indistinguishable from chronic infections such as intestinal tuberculosis, and anti-tuberculosis treatment may be considered prior to further management considerations. The medical management of inflammatory bowel disease depends on subtype classification and severity, and may involve a step-wise approach to immunosuppressive therapies. In children, the consequences of poorly controlled disease are wide ranging, from psychosocial impacts and school non-attendance, to growth impairment and pubertal delay with subsequent impacts on bone health. In addition, an increased need for hospitalization and surgical intervention, and ultimately risk of cancer long-term. A multi-disciplinary team with expertise in inflammatory bowel disease is recommended to mitigate these risks and help to achieve the goal of sustained remission with endoscopic healing. This review focuses on updates on best clinical practice on the diagnosis and management of inflammatory bowel disease in children.
Literature
2.
go back to reference Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990–1007.e3. Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990–1007.e3.
3.
go back to reference Huang JG, Aw MM. Pediatric inflammatory bowel disease in Asia: Epidemiology and natural history. Pediatr Neonatol. 2020;61:263–71.CrossRefPubMed Huang JG, Aw MM. Pediatric inflammatory bowel disease in Asia: Epidemiology and natural history. Pediatr Neonatol. 2020;61:263–71.CrossRefPubMed
4.
go back to reference Roberts SE, Thorne K, Thapar N, et al. A systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe. J Crohns Colitis. 2020;14:1119–48.CrossRefPubMed Roberts SE, Thorne K, Thapar N, et al. A systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe. J Crohns Colitis. 2020;14:1119–48.CrossRefPubMed
5.
go back to reference Pipaliya N, Ingle M, Rathi C, Poddar P, Pandav N, Sawant P. Spectrum of chronic small bowel diarrhea with malabsorption in Indian subcontinent: Is the trend really changing? Intest Res. 2016;14:75–82.CrossRefPubMedPubMedCentral Pipaliya N, Ingle M, Rathi C, Poddar P, Pandav N, Sawant P. Spectrum of chronic small bowel diarrhea with malabsorption in Indian subcontinent: Is the trend really changing? Intest Res. 2016;14:75–82.CrossRefPubMedPubMedCentral
6.
go back to reference Rajbhandari R, Blakemore S, Gupta N, et al. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol. 2020;26:6891–908.CrossRefPubMedPubMedCentral Rajbhandari R, Blakemore S, Gupta N, et al. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol. 2020;26:6891–908.CrossRefPubMedPubMedCentral
7.
go back to reference Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.CrossRefPubMed Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.CrossRefPubMed
8.
go back to reference Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–54.CrossRefPubMed Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–54.CrossRefPubMed
9.
go back to reference Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637–45.CrossRefPubMed Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637–45.CrossRefPubMed
11.
go back to reference Pulimood AB, Peter S, Ramakrishna B, et al. Segmental colonoscopic biopsies in the differentiation of ileocolic tuberculosis from Crohn’s disease. J Gastroenterol Hepatol. 2005;20:688–96.CrossRefPubMed Pulimood AB, Peter S, Ramakrishna B, et al. Segmental colonoscopic biopsies in the differentiation of ileocolic tuberculosis from Crohn’s disease. J Gastroenterol Hepatol. 2005;20:688–96.CrossRefPubMed
12.
go back to reference Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn’s disease. Endoscopy. 2006;38:592–7.CrossRefPubMed Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn’s disease. Endoscopy. 2006;38:592–7.CrossRefPubMed
13.
go back to reference Calabrese E, Maaser C, Zorzi F, et al. Bowel ultrasonography in the management of crohn's disease. a review with recommendations of an international panel of experts. Inflamm Bowel Dis. 2016;22:1168–83. Calabrese E, Maaser C, Zorzi F, et al. Bowel ultrasonography in the management of crohn's disease. a review with recommendations of an international panel of experts. Inflamm Bowel Dis. 2016;22:1168–83.
14.
go back to reference Allocca M, Fiorino G, Bonovas S, et al. Accuracy of humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: A prospective study. J Crohns Colitis. 2018;12:1385–91.CrossRefPubMedPubMedCentral Allocca M, Fiorino G, Bonovas S, et al. Accuracy of humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: A prospective study. J Crohns Colitis. 2018;12:1385–91.CrossRefPubMedPubMedCentral
15.
go back to reference van Wassenaer EA, de Voogd FAE, van Rijn RR, et al. Diagnostic accuracy of transabdominal ultrasound in detecting intestinal inflammation in paediatric ibd patients-A systematic review. J Crohns Colitis. 2019;13:1501–9.CrossRefPubMedPubMedCentral van Wassenaer EA, de Voogd FAE, van Rijn RR, et al. Diagnostic accuracy of transabdominal ultrasound in detecting intestinal inflammation in paediatric ibd patients-A systematic review. J Crohns Colitis. 2019;13:1501–9.CrossRefPubMedPubMedCentral
16.
17.
go back to reference Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35–40.CrossRefPubMed Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35–40.CrossRefPubMed
18.
go back to reference Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389:1710–8.CrossRefPubMedPubMedCentral Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389:1710–8.CrossRefPubMedPubMedCentral
20.
go back to reference Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570–83.CrossRefPubMed Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570–83.CrossRefPubMed
21.
go back to reference Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, Part 1: Ambulatory care-an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91.CrossRefPubMed Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, Part 1: Ambulatory care-an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91.CrossRefPubMed
22.
go back to reference Cezard JP, Munck A, Mouterde O, et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn’s disease: A multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol. 2009;33:31–40.CrossRefPubMed Cezard JP, Munck A, Mouterde O, et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn’s disease: A multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol. 2009;33:31–40.CrossRefPubMed
23.
go back to reference Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2016;9:CD003715. Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2016;9:CD003715.
24.
go back to reference Turner D, Yerushalmi B, Kori M, et al. Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: A randomised controlled trial. J Crohns Colitis. 2017;11:527–33.PubMed Turner D, Yerushalmi B, Kori M, et al. Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: A randomised controlled trial. J Crohns Colitis. 2017;11:527–33.PubMed
25.
go back to reference Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000543. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000543.
26.
go back to reference Swaminath A, Feathers A, Ananthakrishnan AN, Falzon L, Li FS. Systematic review with meta-analysis: Enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2017;46:645–56.CrossRefPubMedPubMedCentral Swaminath A, Feathers A, Ananthakrishnan AN, Falzon L, Li FS. Systematic review with meta-analysis: Enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2017;46:645–56.CrossRefPubMedPubMedCentral
27.
go back to reference Pigneur B, Lepage P, Mondot S, et al. Mucosal healing and bacterial composition in response to enteral nutrition vs steroid-based induction therapy-a randomised prospective clinical trial in children with crohn’s disease. J Crohns Colitis. 2019;13:846–55.CrossRefPubMed Pigneur B, Lepage P, Mondot S, et al. Mucosal healing and bacterial composition in response to enteral nutrition vs steroid-based induction therapy-a randomised prospective clinical trial in children with crohn’s disease. J Crohns Colitis. 2019;13:846–55.CrossRefPubMed
28.
go back to reference Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: A randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–53.CrossRefPubMed Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: A randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–53.CrossRefPubMed
29.
go back to reference Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501–7.CrossRefPubMed Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501–7.CrossRefPubMed
30.
go back to reference Rubio A, Pigneur B, Garnier-Lengline H, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011;33:1332–9. Rubio A, Pigneur B, Garnier-Lengline H, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011;33:1332–9.
31.
go back to reference Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157:440–50.e8. Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157:440–50.e8.
32.
go back to reference Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895–902.CrossRefPubMed Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895–902.CrossRefPubMed
33.
go back to reference Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138–43.CrossRefPubMed Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138–43.CrossRefPubMed
34.
go back to reference Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58 e4; quiz e48–50. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58 e4; quiz e48–50.
35.
go back to reference Carbonnel F, Colombel JF, Filippi J, et al; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150:380–8 e4. Carbonnel F, Colombel JF, Filippi J, et al; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150:380–8 e4.
36.
go back to reference Herfarth H, Barnes EL, Valentine JF, et al; Clinical Research Alliance of the Crohn’s and Colitis Foundation. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018;155:1098–108 e9. Herfarth H, Barnes EL, Valentine JF, et al; Clinical Research Alliance of the Crohn’s and Colitis Foundation. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018;155:1098–108 e9.
37.
go back to reference Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease: A multicentre propensity score study. Gut. 2015;64:1898–904.CrossRefPubMed Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease: A multicentre propensity score study. Gut. 2015;64:1898–904.CrossRefPubMed
39.
go back to reference Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN clinical report: Surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-alpha inhibitors. J Pediatr Gastroenterol Nutr. 2016;63:130–55.CrossRefPubMed Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN clinical report: Surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-alpha inhibitors. J Pediatr Gastroenterol Nutr. 2016;63:130–55.CrossRefPubMed
40.
go back to reference Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655–68.e3. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655–68.e3.
41.
go back to reference El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal crohn's disease in children. inflamm bowel dis. 2019;25:150–5. El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal crohn's disease in children. inflamm bowel dis. 2019;25:150–5.
42.
go back to reference Thavamani A, Umapathi KK, Khatana J, Gulati R. Burden of psychiatric disorders among pediatric and young adults with inflammatory bowel disease: A population-based analysis. Pediatr Gastroenterol Hepatol Nutr. 2019;22:527–35.CrossRefPubMedPubMedCentral Thavamani A, Umapathi KK, Khatana J, Gulati R. Burden of psychiatric disorders among pediatric and young adults with inflammatory bowel disease: A population-based analysis. Pediatr Gastroenterol Hepatol Nutr. 2019;22:527–35.CrossRefPubMedPubMedCentral
44.
go back to reference Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–53.CrossRefPubMed Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–53.CrossRefPubMed
Metadata
Title
Inflammatory Bowel Disease in Children
Authors
Asha Jois
George Alex
Publication date
20-06-2023
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 5/2024
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-023-04671-0

Other articles of this Issue 5/2024

Indian Journal of Pediatrics 5/2024 Go to the issue